Exactly, Survivor. I see this trial is 2017. I believe I saw it back then. I’m hoping it can be an early signal that the immunotherapy is working so as to shorten trials. As you noted.
I suppose it is one if several things being introduced as ancillary evidence in the L SAP. Hence the need for very mature data to strengthen correlations to survival based on various observations. This being accepted would lead to acceptance in Direct trials along with use of evidence found in the patent claims related to known responders. This wait will be proven to be well worth it. Best wishes.